Conclusion
CSVT is an important complication of ALL treatment, especially in areas
where its incidence is reported to be high as in Lebanon. Some risk
factors have been previously identified and our study was able to
augment with novel and additional risk factors that have not been
previously discussed (Triglyceride level > 615 mg/dL,
mediastinal mass and body surface area in multivariate analysis). Given
the poor literature and recommendation consensus in relation to CSVT
prophylaxis and the newly unveiled risk factors that are highlighted in
our study, we recommend further prospective studies with larger samples
to confirm our findings and help identify the subgroup of patients that
qualify for CSVT prophylaxis during ALL treatment.